AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 DEC 1 - (NewsRx.com & NewsRx.net) -- Targeted Genetics Corporation (TGEN) announced its financial results for the third quarter of 2004.
Revenue for the third quarter of 2004 was $2.4 million compared to $5.0 million for the third quarter of 2003. Revenue for the 9 months ended September 30, 2004 decreased to $6.5 million from $12.7 million for the same period of 2003.
Revenues in 2004 reflect amounts earned under the company's AIDS vaccine collaboration with the International AIDS Vaccine Initiative (IAVI) and the Columbus Children's Research Institute, which increased in 2004 compared to 2003, and to a lesser degree contract manufacturing revenue earned in the first quarter of 2004.
The company reported a net loss of $2.7 million, for the quarter, or $0.03 per common share, compared to a net loss of $780,000, or $0.01 per common share for the third quarter of 2003. For the 9 months ended September 30, 2004, the ...